RESPIRATORY INFECTIONS ARE A LEADING CAUSE OF HOSPITALIZATION
The severity of flu seasons is usually reported at the population level, but clinical scores measuring individual-level disease severity are urgently needed.
Here is a simple tool to assess your patients’ symptoms – or your own.
During a regular flu season, community clinics and emergency rooms are often overcrowded, and it is difficult to assess quickly how patients are doing. With staff rapid turnover and in between emergency room or hospital shifts, important information may get lost. ICU and hospital beds need to be used for those who need them most, and understanding a patient's trajectory over time is critical.
This issue has become exacerbated to unprecedented levels during the COVID-19 pandemic.
In 3 minutes, providers can score the severity of their patients’ illness, allowing for better care and better resource allocation.
Regular people, sitting in their homes, can also use the ViVI Score. It will help to give piece of mind when symptoms are mild or inform individuals when it is time to go to the doctor.
Here is a simple tool to assess your patients’ symptoms – or your own.
During a regular flu season, community clinics and emergency rooms are often overcrowded, and it is difficult to assess quickly how patients are doing. With staff rapid turnover and in between emergency room or hospital shifts, important information may get lost. ICU and hospital beds need to be used for those who need them most, and understanding a patient's trajectory over time is critical.
This issue has become exacerbated to unprecedented levels during the COVID-19 pandemic.
In 3 minutes, providers can score the severity of their patients’ illness, allowing for better care and better resource allocation.
Regular people, sitting in their homes, can also use the ViVI Score. It will help to give piece of mind when symptoms are mild or inform individuals when it is time to go to the doctor.
THE VIVI SCORE HAS PROVEN EFFECTIVE
Use of the ViVI Score has been shown to improve quality of care, doctor-patient communication, vaccine effectiveness surveillance, pandemic preparedness, antibiotic stewardship, as well as the accuracy and interoperability of clinical trial data.1,2,3
The tool works across the pediatric and adult age spectrum, for patients with mild cold symptoms all the way to severe cases requiring intensive care, and during initial evaluations as well as during follow-up visits.4,5 The mobile application is available in multiple languages; a special edition for patient reported outcome measures is underway.
The Score has since been validated in more than 8000 patients at major academic hospitals in Europe in collaboration with public health agencies, and is now also used in decentralized community clinics and intensive care units in the USA.1
The tool works across the pediatric and adult age spectrum, for patients with mild cold symptoms all the way to severe cases requiring intensive care, and during initial evaluations as well as during follow-up visits.4,5 The mobile application is available in multiple languages; a special edition for patient reported outcome measures is underway.
The Score has since been validated in more than 8000 patients at major academic hospitals in Europe in collaboration with public health agencies, and is now also used in decentralized community clinics and intensive care units in the USA.1
1. Rath B. The ViVI Disease Severity Score. Duke Margolis Center/ FDA Workshop: ‘Advancing Drug Development for Respiratory Syncytial Virus’. Washington, DC, USA: Duke Margolis Center; 2016.
2. Rath B, Conrad T, Karsch K, Tief F, Obermeier P, Chen X, Seeber L, Adamou E, Reiche J, Schweiger B. A Standardized Clinical Outcome Parameter for Infants and Children with Influenza-like Illness (ILI). 3rd ISIRV Antiviral Group Conference, ‘Influenza and Other Respira- tory Virus Infections: Advances in Clinical Management’; 2014; Tokyo, Japan.
3. Tief F, Hoppe C, Seeber L, Obermeier P, Chen X, Karsch K, Muhlhans S, Adamou E, Conrad T, Beresniak A, Schweiger B, Adam T, Rath B. An inception cohort study assessing the role of pneumococcal and other bacterial pathogens in children with influenza and ILI and a clinical decision model for stringent antibiotic use. Antivir Ther. 2016;21(5):413–24. doi:10.3851/IMP3034. PMID:26867096.
4. Rath B, Conrad T, Myles P, Alchikh M, Ma X, Hoppe C, Obermeier P, Kisler B, Schweiger B. Influenza and other respiratory viruses: stan- dardizing disease severity in surveillance and clinical trials. Expert Review of Anti-infective Therapy. 2017;15(6):545–68. doi:10.1080/ 14787210.2017.1295847. PMID:28277820.
5. Karsch K, Chen X, Miera O, Peters B, Obermeier P, Francis RC, Amann V, Duwe S, Fraaij P, Heider A, de Zwart M, Berger F, Oster- haus A, Schweiger B, Rath B. Pharmacokinetics of Oral and Intrave- nous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. Eur J Drug Metab Pharmaco- kinet. 2016;42(1):155–64. doi:10.1007/s13318-016-0330-9.
2. Rath B, Conrad T, Karsch K, Tief F, Obermeier P, Chen X, Seeber L, Adamou E, Reiche J, Schweiger B. A Standardized Clinical Outcome Parameter for Infants and Children with Influenza-like Illness (ILI). 3rd ISIRV Antiviral Group Conference, ‘Influenza and Other Respira- tory Virus Infections: Advances in Clinical Management’; 2014; Tokyo, Japan.
3. Tief F, Hoppe C, Seeber L, Obermeier P, Chen X, Karsch K, Muhlhans S, Adamou E, Conrad T, Beresniak A, Schweiger B, Adam T, Rath B. An inception cohort study assessing the role of pneumococcal and other bacterial pathogens in children with influenza and ILI and a clinical decision model for stringent antibiotic use. Antivir Ther. 2016;21(5):413–24. doi:10.3851/IMP3034. PMID:26867096.
4. Rath B, Conrad T, Myles P, Alchikh M, Ma X, Hoppe C, Obermeier P, Kisler B, Schweiger B. Influenza and other respiratory viruses: stan- dardizing disease severity in surveillance and clinical trials. Expert Review of Anti-infective Therapy. 2017;15(6):545–68. doi:10.1080/ 14787210.2017.1295847. PMID:28277820.
5. Karsch K, Chen X, Miera O, Peters B, Obermeier P, Francis RC, Amann V, Duwe S, Fraaij P, Heider A, de Zwart M, Berger F, Oster- haus A, Schweiger B, Rath B. Pharmacokinetics of Oral and Intrave- nous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. Eur J Drug Metab Pharmaco- kinet. 2016;42(1):155–64. doi:10.1007/s13318-016-0330-9.